Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Univercell Biosolutions is a French biotechnology company specializing in the development and production of high-quality human cell models derived from induced pluripotent stem cells (iPSCs). The company provides "ready-to-use" human cells, such as cardiomyocytes, hepatocytes, and skeletal muscle cells, to the pharmaceutical, cosmetic, and academic sectors for drug discovery, safety pharmacology, and disease modeling. By leveraging its proprietary differentiation protocols, Univercell Biosolutions enables researchers to work with physiologically relevant human models that better mimic human biology compared to traditional animal models. In addition to its catalog of cell products, the company offers custom cell engineering and assay development services to support specialized research requirements. Their technology aims to improve the predictability of preclinical studies and accelerate the development of new therapeutic candidates.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Univercelle-Biosolutions.